title: Photodynamic therapy with verteporfin for choroidal neovascularization associated with angioid streaks.
abstract: BACKGROUND
  Choroidal neovascularizations (CNV) is the major cause of significant visual loss in patients with angioid streaks. We evaluated the functional and morphological outcome of Verteporfin photodynamic therapy (PDT) in the treatment of these patients.
  
  
  METHODS
  This was a retrospective study in two tertiary referral centres over a 3-year period. Examinations included visual acuity assessment with ETDRS charts, binocular fundoscopy and fluorescein angiography. PDT was performed with standard parameters; earlier retreatments were feasible in active CNV.
  
  
  RESULTS
  Fifteen eyes from 12 patients (9 male, 3 female) with a follow-up of 12-50 months (mean 26.1, median 19 months) were included. Five lesions were extra-or juxtafoveal and ten were subfoveal. Baseline visual acuity was between 20/63 and 20/16 (mean 20/32, median 20/32). Eyes were treated with two to eight treatments of PDT (mean 4.2, median 4). Treatment intervals were between 5.6 and 72 weeks (mean 12.1, median 9.2 weeks). At the 1-year follow-up, visual acuity was below 20/200 in 27% (4/15), 20/200 or better in 73% (11/15) and 20/63 or better in 47% (7/15) with an improvement of >3 lines in 13% (2/15), no change in 27% (4/15) and a decrease of >3 lines in 60% (9/15). At the final follow-up examination, all lesions were located subfoveally. Visual acuity was below 20/200 in 47% (7/15), 20/200 or better in 53% (8/15) and 20/63 or better in 13% (2/15) with a change in visual acuity between +2 and -18 lines (mean -9 lines, median -8 lines). No change was noted in 7% (1/15) and a decrease of >3 lines in 93% (14/15) of eyes. The maximum measured greatest linear dimension of the lesion during the follow-up varied between 2400 microm and 6200 microm (mean 3680 microm, median 3600 microm) with an increase in the lesion size compared with baseline values between +/-0 microm and +3700 microm (mean+1420 microm, median+1500 microm).
  
  
  CONCLUSIONS
  PDT for CNV associated with angioid streaks seemed to slow down but not prevent the progression of the disease and associated visual loss. Further modifications of the treatments parameters or a combination with other therapeutical options seem warranted for a more effective treatment of these lesions.
authors.affiliation: St. Paul's Eye Unit, Royal Liverpool Hospital, Prescot Street, Liverpool, L7 8XP, UK. heinrichheimann@yahoo.de
authors.forename: Heinrich
authors.initials: H
authors.lastname: Heimann
authors.forename: Faik
authors.initials: F
authors.lastname: Gelisken
authors.forename: Joachim
authors.initials: J
authors.lastname: Wachtlin
authors.forename: Andreas
authors.initials: A
authors.lastname: Wehner
authors.forename: Michael
authors.initials: M
authors.lastname: Völker
authors.forename: Michael H
authors.initials: MH
authors.lastname: Foerster
authors.forename: Karl Ulrich
authors.initials: KU
authors.lastname: Bartz-Schmidt
mesh_terms: D000328:Adult; D000368:Aged; D000793:Angioid Streaks / Q000150:complications / Q000188:drug therapy*; D020256:Choroidal Neovascularization / Q000150:complications / Q000188:drug therapy*; D005260:Female; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000627:therapeutic use*; D011166:Porphyrins / Q000627:therapeutic use*; D012189:Retrospective Studies; D000077362:Verteporfin; D014792:Visual Acuity
chemical_list: D017319:Photosensitizing Agents; D011166:Porphyrins; D000077362:Verteporfin